August 20, 2021
Authored and Edited by Jeffrey A. Freeman; Thomas L. Irving; Stacy Lewis*
In Chemours Company FC, LLC v. Daikin Industries, Ltd., Nos. 20-1289, -1290 (Fed. Cir. July 22, 2021), a CAFC panel held that the PTAB (“Board”) erred by finding the very patent at issue in an IPR to be a “blocking patent” and that the proffered sales evidence of commercial success was therefore “weak.”
A “blocking patent” is an earlier U.S. patent that prevents practice of a later invention. In some instances, the CAFC has found that such prior blocking patents may reduce the weight given to objective indicia of nonobviousness, such as failure of others, long-felt but unmet need, and commercial success. The rationale is that the existence of the prior blocking patent may have dissuaded or legally barred competitors from commercializing the purportedly obvious idea, thus rendering weak the normal inference of nonobviousness resulting from such objective indicia. See, e.g., Acorda Therapeutics, Inc. v. Roxane Labs., Inc., 903 F.3d 1310 (Fed. Cir. 2018); Sanofi-Aventis Deutschland GMBH v. Mylan Pharms. Inc., 791 Fed. Appx. 916 (Fed. Cir. 2019); and Galderma Labs., L.P. v. Tolmar, Inc., 737 F.3d 731 (Fed. Cir. 2013).
In Chemours, the Board evaluated the obviousness of Chemours’ patent, including sales evidence proffered by Chemours for its commercial polymer FEP 9494 covered by the patent. The Board determined Chemours evidence of commercial success was weak because it concluded that the existence of the patent covering its FEP 9494 product was a blocking patent that would have precluded others from freely entering the market. Chemours, at *16.
The CAFC reversed, finding the Board erred by misapplying the “blocking patent” doctrine to the patent at issue itself. Id. The CAFC explained that “[a] blocking patent is one that is in place before the claimed invention because ‘such a blocking patent may deter non-owners and non-licensees from investing the resources needed to make, develop, and market such a later, ‘blocked’ invention.’” Id. In view of this explanation, the CAFC concluded that “the challenged patent, which covers the claimed invention at issue, cannot act as a blocking patent.” Id. at *16-17.
The burden of showing obviousness is on the examiner during prosecution, on the petitioner in an AIA Post Grant Proceeding and on the challenger in district court litigation. MPEP §2142; Novo Nordisk A/S v. Caraco Pharm. Labs., Ltd., 719 F.3d 1346 (Fed. Cir. 2013). Patent owners may have strong commercial success arguments as to why that burden has not been met, as in the Chemours case where the blocking patent doctrine was being misapplied. Of course, the patent owner would have to overcome attacks that there is no nexus between the merits of the claimed invention and that the commercial success is not commensurate in scope with the claimed invention. Chemours also dealt with those issues, and we shall deal with them in a separate post entitled “Objective Indicia: Nexus Analysis May Require Evaluation of Claims as a “Unique Combination”.
secondary considerations of non-obviousness, United States Court of Appeals for the Federal Circuit (CAFC), blocking patent
*Stacy Lewis is a Law Clerk at Finnegan.
Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.